The purpose of this study wu to evaluate the iD vivo effect of FK506 on human pancreatic isiets. Twentyfive Dude mice were made diabetic by one iDtraveDous injection of streptozotociD. Approximately 600 islets were admiDistered iD the renal subea~ular space 3-5 days followiDg streptozotociD admiDistratioD. ODe week ..cter traDsplaDtatioD, the mice were divided iD four groups. ID group 1. the lUlimals received 1 injectioD of 0.6 ml of dilueDt i.p. daily for one week. ID groups 2. 3. Uld 4 the treatmeDts were daily i.p. iDjectioD of 0.3. 1. and 3 mil kg FK506. respectively. After treatment, the rUDctional iDtegrity of the trlUllPllUlted humaD islets wu tested by meuuriDg the pluma glucose and humaD C·peptide response to iDtraperitoneal gluCOBe injection in groups 1 and 4. IPGTT aloDe wu aueaed in groups 2 and 3. The renits iDdicate that i.p. admiDistration of I Thia woric wu lupponed by ReulU'Cb Granu trom the Veteraftl .\dminlltrauon and by ProjlCl Grant 29961 from the National Inlti· rutH of Health. Betheacia. MD.
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FK508 (or one week at a dose 0.3 mg/kg/day did not result in any significant aiteration of glucose disappearance and C-peptide response to IPGTT. Higher doaes of FK506 produced a significant delay in gluCOBe disappearance in groups 3 and 4. and a 8ignificant inhibition of glucose-mediated C-peptide response iD group 4 .
FK506 has recently joined the growing list of new pharmaceuticals with potent immunosuppressive properties ( 1). Post· tranaplant hyperglycemia is a well recognized side effect of moat standard immunosuppressive drugs, including prednisone (2) and cyclosporine A (3) (4) (5) . which are known to be diabetogenic in men. Similar effecta have been ascribed to FK506 in both experimental (6. 7) and clinical studies (8) . As clinical experience is successfully extended. there wlil be new applicationa for the drug besides whole organ transplantation. FK506 haa been recently used as a main immunosuppresaive agent in clinical trials of islet transplantation «9\. In addition. intervention triala of FK506 in the treatment of newoOnset type I diabetes mellitus are planned. The aim of this atudy was to teat the in vivo effect of FK506 on human pancreatic isleta.
TRANSPLANTATION MATERIALS AND METHODS
HwnIJI& Ltlet iaoiatiDn. Human illeta were prepand from c:adaver donor panc:re .... obtained from muitiorpD donora UO, 11) . After in litu perfusion of the abdominal aorta with 1500-2000 mJ of University of Wiac:onsin solution (UW) additional 500-1000 ml of UW was infused direc:tiy into the liver via the portal vein. Venous hypertension of the pauc:rea "'a avoided by venting the portal andlor spleniC: vein. The pauc:rea ",al immersed in UW and packed in ice until the islet isolation began. The isleta were isolated.. previously described (9, 12) . Briefiy, after intraduc:tal injection of 350 ml of Hanb' solution containing 2 ml/mJ collqenae (Boehrinpr-MlDDheim. type P) the pauerea "'. loaded into a ItaiDleu lteel dipetion chamber and the isleta were separated. durin( a conUnuoua d.ipetion proc:etl that lasted 40-50 min (12) . The isleta were purified by cenuifuption on Euroc:olliDa-Ficoll grad.ienta (denaity -1.108. 1.096, 1.037) using a COBE 2991 cell separator (COBE Laboratories. Lakewood. CO) (9) .
AninacUa. Mala BALBlc nude mice (16-20 g body ",eight) were used a illet recipienta. The anima.Ia were made diabetic by one intravenoua injection of ItreptozotociD (165 me/kr).
HwnIJI& Ltlec t~n. Only mice with nonfaating pluma glUCOle >400 mg/cIl were used a recipienta of hWIWI isletl. Each IDima.I received an aliquot of approzimately 600 human ialm of 150-,. diameter (13) 3-6 da" after .treptozotoc:iD administration. The weta were transplanted. beneath the left renal capluie a previously described (14) .
Treatment. FK506 (10 mg) "'. diuolved in a minure of cremaphor (625 mg) and ethanol (328 mg). This solution ",a diluted with norma! aaline to give a concentration of 100 mg/ml. The aaline solution of FK506 "'. prepared fresh daily for injection.
One week after hWIWI iaIet transplantation the animaia were divided in four groups. In group 1 (n-10). the animaIa received one injection of 0.5 ml of c:remaphor-ethauol-u.line (without FK506) i.p. daily for on. week. In group 2 (n-6) the anima.Ia were treated by daily i.p. injection of 0.3 mllkr FK506, ",hile in groupa 3 (n-6) and 4 (n-6) the daily injectiona were 1 and 3 mg/k, FK506, reapectively.
InlIaperitDrwal ,iuI:oIe tDleratU:e te,t, At 15 da" after illet transplantation. the animala underwent IPGTT CIS). The animaIa ",ere futed overnight (18 hr) and then injected inUaperitoneally ",ith 25' " glUCOlland 0.9'" sodium c:hloride solution (2, rlucoN/kg body weight). Blood IlUDple. were obtained before (0 min) and 15, 30, and 60 min after gluc:oN injection and analyzed for plama IluCOll and human Cpeptide levelL PWmtJ ,tucoae and hwnlJl& C·peptVJ. determination. Whole-blood (100 1&1) "'. collected into mic:rohematocrit capillary tubea and placed on ice. Plume "'. prepared by centrifu.ation at 10.000 xg for 3 StotUtiaJlGMlyli&. All resulta are ezpreued. meana ~ SO AN "'U uaed to compare differences between groupa. and P v".! o\' ~ given. meuurea of .tatiatical aigniflCaJlCe.
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RESULTS
The results are summarized in Tables 1 and 2 • Plasma rluc:oae levela 0, 15. 30, and 60 min followin,an intrapen.
toneai gluc:oae toleranca teat performed 15 da" after hUDI8D ia1et
tranaplantation beneath the renal capsule of diabetic nude mice. batra.
peritoneal adminiatration of FK506 for 1 week before the teat produceci a doee-dependent efrect on ,luc:oee disappearance.
• • P<O.028. with an mitial impairment of insulin secretion from the en· &rifted isleta. In fact. 15 min after glucose injection a decrease ill buman C·peptide levels wu observed in group 4. in controt to the control groups, in which a two fold increase in C-peptide .... ohserved. The difference in C-peptide level. between the t1to troups was statistically significant only st the 1S-min level (P<o.028).
. The determination of plasma FK levels after IPGTT resulted 1.11 an average of 3.8±2.8 ng/ml (group 2). 106.6±6.3 ng/ml (croup 3). and 303.S±173.7 ng/ml (group 4).
Hiatologic studies of the renal subcapsular isleta indicated that human islets were present in the renal subcapsular space at ttl transplanted animals. Neverthelesa. in tbe 2 animals 11 ill croup 3 and 1 in group 4) who were hyperglycemic. the beta ctlla appeared de~ulated. In the remaining animals the t.u.an Islets appeared well·preserved. with no lignificant dif· _ee between FK506 treated and control animala. In group 1 (controll a nephrectomy of the kidneyt beann, the grafts IItoduced a rapid retum to the diabetic ltate. indicating that ta. human taleta tranapluted were responsible for the main--. . . of normoglycemiL DISCUSSION This study indicates that FK506 did not produce significant alteration of glucose homeostasis in animals treated with a dose of 0.3 mg/kg/day for 7 dayt. Nevertheless. the efrecta of the drug on insulin secretion and glucose disappearance after intraperitoneal glucose have been observed at higher doses. These efrecta appear to be doae-dependent and are obaerved with serum FK506 levels that are significantly higher than thera· peutic levels achieved in man. Although these levels are lignificantiy higher than the therapeutic levels in current use in patients, the potential accumulation during chronic treatment with the agent in the pancreas, like cyciosporine, may induce islet secretory defects even at therapeutic levels. In addition. the pharmacodynamici of FK506 may differ between the two species.
These findings confirm the results of previous reports on the effect FK506 on rat and human islets in vitro (19) . Further studies are needed to determine whether the toxic effect of FK506 observed at higher doses is reversible upon discontinuation of treatment.
